THE NOVEL DUAL DELAYED-RELEASE PROTON PUMP INHIBITOR DEXLANSOPRAZOLE (DEXILANT®)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper provides a current review of the specific features of the pharmacokinetics of the novel innovative dual delayed-release proton pump inhibitor (PPI) dexlansoprazole (Dexilant®). Due to its two-step release and increased blood residence time, the drug has shown the high efficacy in treating different forms of gastroesophageal reflux disease, which is greater to that of other PPIs in terms of a number of indicators, and ensures higher patient adherence to treatment.

Full Text

Restricted Access

About the authors

M. Osipenko

Novosibirsk State Medical University

Email: ngma@bk.ru
Professor

S. Kholln

Novosibirsk State Medical University

Email: ngma@bk.ru
Candidate of Medical Sciences

References

  1. Sachs G., Shin J., Howden C. Review article: the clinical pharmacology of proton pump inhibitors // Aliment. Pharmacol. Ther. - 2006; 23 (suppl. 2): 2-8.
  2. Metz D., Ferron G., Paul J. et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study // J. Clin. Pharmacol. - 2002; 42: 512-9.
  3. Sachs G., Shin J., Vagin O. et al. The Gastric H, K ATPase of a Drug Target: past, present, and future // J. Clin. Gastroenterol. - 2007; 41 (Suppl. 2): 226-42.
  4. Dent J., Brun J., Fendrick A. et al. An evidence-based appraisal of reflux disease management-the Geneva Workshop report // Gut. - 1999; 44 (Suppl. 2): 1-16.
  5. DeVault K., Castell D. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease // Am. J. Gastroenterol. - 2005; 100: 190-200.
  6. Chey W., Inadomi J., Booher A. et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey // Am. J. Gastroenterol. - 2005; 100: 1237-42.
  7. Tonini M., DeGiorgio R., DePonti F. Novel therapeutic strategies in acid-related disorders // Exp. Opin. Ther. Patents. - 2003; 13: 639-49.
  8. Hunt R. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 // Aliment. Pharmacol. Ther. - 2005; 22 (Suppl. 3): 10-9.
  9. Bate C., Booth S., Crowe J. et al. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? // Aliment. Pharmacol. Ther. -1993; 7: 501-7.
  10. Claxton A., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance // Clin. Ther. - 2001; 23: 1296-310.
  11. Miner P., Katz P., Chen Y. et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study // Am. J. Gastroenterol. - 2003; 98: 2616-20.
  12. Behm B., Peura D. Dexlansoprazole MR for the management of gastroesophageal reflux disease // Expert Rev. Gastroenterol. Hepatol. - 2011; 5: 439-45.
  13. Vakily M. et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials // Curr. Med. Res. Opin. - 2009; 25: 627-38.
  14. Metz D., Vakily M., Dixit T. et al. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy // Aliment. Pharmacol. Ther. - 2009; 29: 928-37.
  15. Chey W., Inadomi J., Booher A. et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey // Am. J. Gastroenterol. - 2005; 100: 1237-42.
  16. Persson K. When do ulcer patients take their acid inhibiting medication? // Hassle Information. - 1993; 7: 19-23.
  17. Solem C., Mody R., Stephens J. et al. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: Physician knowledge, patient adherence // J. Am. Pharm. Assoc. - 2014; 54: 144-53.
  18. Nexium (esomeprazole magnesium). Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
  19. Sostek M., Chen Y., Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole // Br. J. Clin. Pharmacol. -2007; 64: 386-90.
  20. Vaz-da-Silva M., Loureiro A., Nunes T. et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions // Clin. Drug. Investig. - 2005; 25: 391-9.
  21. Bergstrand R., Grind M., Nyberg G. et al. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast // Clin. Drug. Invest. - 1995; 9: 67-71.
  22. Lee R., Vakily M., Mulford D. et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility // Aliment. Pharmacol. Ther. - 2009; 29: 824-33.
  23. Lee R., Mulford D., Wu J. et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor // Aliment. Pharmacol. Ther. - 2010; 31: 1001-11.
  24. Nexium (esomeprazole magnesium) Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
  25. Prilosec (Omeprazole). Full Prescribing Information. Wilmington, DE: AstraZeneca LP, 2008.
  26. Prevacid (lansoprazole). Full Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2009.
  27. Lee R., Mulford D., Wu J. et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor // Aliment. Pharmacol. Ther. - 2010; 31: 1001-11
  28. Kapidex (dexlansoprazole). Full Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2009.
  29. Kukulka M., Eisenberg C., Nudurupati S. Comparator pH study to evaluate the singledose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg // Clin. Exp. Gastroenterol. - 2011; 4: 213-20.
  30. Nojkov B., Rubenstein J., Adlis S. et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease // Aliment. Pharmacol. Ther. -2008; 27: 473-82.
  31. Nocon M., Labenz J., Jaspersen D. et al. Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - results from the ProGERD study // Aliment. Pharmacol. Ther. - 2007; 25: 715-22.
  32. Sharma P., Shaheen N., Perez M. et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies // Aliment. Pharmacol. Ther. - 2008; 29: 731-41
  33. Donnellan C., Sharma N., Preston C. et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease // Cochrane Database Syst. Rev. - 2004: CD003245.
  34. Metz D., Howden C., Perez M. et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis // Aliment. Pharmacol. Ther. - 2009; 29: 742-54.
  35. Fass R. Proton pump inhibitor failure-what are the therapeutic options? // Am. J. Gastroenterol. - 2009; 104 (Suppl. 2): 33-8.
  36. Kahrilas P., Shaheen N., Vaezi M. et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease // Gastroenterology. - 2008; 135: 1383-91.
  37. Chey W., Mody R., Wu E. et al. Treatment patterns and symptom control in patients with GERD: US community-based survey // Curr. Med. Res. Opin. - 2009; 25: 1869-78.
  38. Heidelbaugh J., Goldberg K., Inadomi J. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected] // Am. J. Gastroenterol. - 2009; 104 (Suppl. 2): 27-32.
  39. Fass R., Inadomi J., Han C. et al. Maintenance of Heartburn Relief After Step-Down From Twice-Daily Proton Pump Inhibitor to Once-Daily Dexlansoprazole Modified Release // Clin. gastroenterol. hepatol. - 2012; 10: 247-53.
  40. Dean B., Gano A.-Jr., Knight K. et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease // Clin. Gastroenterol. Hepatol. - 2004; 2: 656-64.
  41. Fass R., Chey W., Zakko S. et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease // Aliment. Pharmacol. Ther. - 2009; 29: 1261-72.
  42. Mody R., Bolge S., Kannan H. et al. Effects of gastroesophageal refl ux disease on sleep and outcomes // Clin. Gastroenterol. Hepatol. - 2009; 7: 953-9.
  43. Fass R., Johnson D., Orr W. et al. The Effect of Dexlansoprazole MR on Nocturnal Heartburn and GERD-Related Sleep Disturbances in Patients With Symptomatic GERD // Am. J. Gastroenterol. - 2011; 106: 421-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies